OncoMatch

OncoMatch/Clinical Trials/NCT07084662

Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

Is NCT07084662 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Xinlikang capsules and mimic capsules for diffuse large b-cell lymphoma (dlbcl).

Phase 2/3RecruitingSun Yat-sen UniversityNCT07084662Data as of Jun 2026Location: China

Treatment: Xinlikang capsules · mimic capsulesTo evaluate the efficacy and safety of Xinlikang capsule in the treatment of cancer-related fatigue (CRF) and peripheral blood lymphocytes in patients with diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) after all courses of chemotherapy-containing regimens

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Xinlikang capsulesmimic capsules

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Prior therapy

Min 1 prior line

Must have received: chemotherapy — first-line

Patients had completed the first-line treatment of chemotherapy and immunotherapy and the course of treatment had been completed.

Must have received: immunotherapy — first-line

Patients had completed the first-line treatment of chemotherapy and immunotherapy and the course of treatment had been completed.

Lab requirements

Blood counts

white blood cell ≤1.0×10^9/L, neutrophil ≤0.5×10^9/L, platelet ≤30×10^9/L, hemoglobin ≤6g/dL

Kidney function

BUN and Cr≥3 ULN

Liver function

ALT, AST, GGT≥3 ULN

Significant abnormal liver and kidney function: ALT, AST, GGT≥3 ULN; BUN and Cr≥3 ULN; Severe abnormal bone marrow function: white blood cell ≤1.0×10^9/L, neutrophil ≤0.5×10^9/L, platelet ≤30×10^9/L, hemoglobin ≤6g/dL

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07084662 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received chemotherapy and immunotherapy.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify